^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    navtemadlin (KRT-232) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Vanderbilt University Medical Center
    Title:

    Study explores melanoma drug’s effectiveness

    Published date:
    04/23/2020
    Excerpt:
    KRT-232 was found to be effective as a monotherapy for tumors with typical BRAF status and was effective as a combination therapy with BRAF mutant tumors when paired with the targeted therapies dabrafenib and trametinib....KRT-232 with trametinib was shown to reduce tumor size in 73% of patients without BRAF mutation. It reduced tumor size in 100% of patients with BRAF mutant tumors when combined with trametinib or dabrafenib.